A new biotech venture firm emerges, led by Bob Langer's son [Yahoo! Finance]
Voyager Therapeutics, Inc. (VYGR)
Last voyager therapeutics, inc. earnings: 3/3 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.voyagertherapeutics.com
Company Research
Source: Yahoo! Finance
A new venture fund co-founded by the son of serial biotechnology entrepreneur Bob Langer announced the close of its first fund on Thursday, banking $77.5 million. Called T.Rx Capital, the firm aims to invest in ten to 15 companies working at the “intersection of technology and biology,” which it described in a statement as including biotechs, “ techbio ” startups and those specializing in “tech-enabled services.” In an email to BioPharma Dive, Michael Langer, the son of Bob Langer and one of the firm's three founders, wrote that, within drug development, the company will consider investments in “next-generation modalities” like cell and gene therapies, radiopharmaceuticals and novel biologics. Outside of that scope, the firm is interested in AI-driven drug discovery, as well as digital tools that might speed development. The team sees a “unique deal flow to early stage companies,” he said, from its ability to draw ideas from a network of more than 1,000 alumni who have worked i
Show less
Read more
Impact Snapshot
Event Time:
VYGR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VYGR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VYGR alerts
High impacting Voyager Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VYGR
News
- Voyager Therapeutics (NASDAQ:VYGR) had its price target lowered by analysts at HC Wainwright from $30.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- Voyager Therapeutics (NASDAQ:VYGR) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.MarketBeat
- Voyager Reports Third Quarter 2025 Financial and Operating Results [Yahoo! Finance]Yahoo! Finance
- Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia [Yahoo! Finance]Yahoo! Finance
- Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal DementiaGlobeNewswire
VYGR
Earnings
- 11/10/25 - Beat
VYGR
Sec Filings
- 12/2/25 - Form EFFECT
- 12/1/25 - Form 424B3
- 11/14/25 - Form SCHEDULE
- VYGR's page on the SEC website